Traders Purchase Large Volume of United Therapeutics Call Options (NASDAQ:UTHR)

United Therapeutics Corporation (NASDAQ:UTHR) was the target of some unusual options trading on Monday. Investors bought 16,791 call options on the stock. This is an increase of approximately 789% compared to the average volume of 1,888 call options.

Insider Activity

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $471.91, for a total value of $10,617,975.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total transaction of $4,654,145.00. Following the transaction, the chief executive officer directly owned 130 shares of the company’s stock, valued at $63,688.30. The trade was a 98.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 333,820 shares of company stock valued at $165,495,478 in the last quarter. Insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently made changes to their positions in the company. Torren Management LLC acquired a new position in United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management raised its stake in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC acquired a new stake in United Therapeutics during the 4th quarter worth approximately $31,000. Wilmington Savings Fund Society FSB lifted its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $48,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Up 12.5%

Shares of UTHR stock opened at $588.36 on Tuesday. The company has a market cap of $25.79 billion, a P/E ratio of 21.09, a PEG ratio of 1.88 and a beta of 0.84. The firm has a fifty day moving average price of $498.42 and a 200 day moving average price of $474.96. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $607.89.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the firm earned $6.19 earnings per share. On average, equities analysts forecast that United Therapeutics will post 24.48 EPS for the current year.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 (Tyvaso) pivotal success — the 598‑patient Phase 3 trial met its primary endpoint, showing a Hodges‑Lehmann estimate of +130.1 mL change in absolute FVC at week 52 vs. placebo, a clinically meaningful result that expands Tyvaso’s potential market beyond PAH. Read More.
• Positive Sentiment: Ralinepag Phase 3 readout + buyback momentum — investors are still digesting positive ADVANCE OUTCOMES ralinepag data (large reduction in clinical‑worsening risk) and United Therapeutics’ board authorized up to $2B in buybacks with ~$1.5B in ASRs, which accelerates share‑count reduction and supports EPS. Read More.
• Positive Sentiment: Surge in call‑option activity — unusually large options flow (≈16,800 calls, ~789% above normal) signals bullish positioning and likely amplified intraday upside through speculative buying and short‑covering. (Market data entry)
• Positive Sentiment: Analyst lift — TD Cowen raised its price target to $660 and reiterated a Buy view, which likely reinforced investor conviction after the clinical news. Read More.
• Neutral Sentiment: Read‑through to peers — some smaller respiratory/rare‑disease names saw moves on trial read‑throughs and analyst notes (e.g., Insmed), but the competitive or regulatory implications for other firms remain speculative. Read More.
• Negative Sentiment: Insider selling — CEO Martine Rothblatt sold 9,500 shares on March 26, and public filings show extensive insider sales over recent months; while not unusual for a high‑value stock, heavy insider disposals can be perceived as a headwind by some investors. Read More.

Analysts Set New Price Targets

Several equities analysts have commented on UTHR shares. UBS Group boosted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. HC Wainwright lifted their target price on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Royal Bank Of Canada upped their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $557.64.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.